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Objectives This study sought to report the long-term outcomes after drug-eluting stent (DES) im-
plantation in saphenous vein graft (SVG) lesions in the SOS (Stenting of Saphenous Vein Grafts) trial.
Background The long-term outcomes after DES implantation in SVGs are poorly studied. Apart from
the SOS trial, the only other randomized trial comparing DES with bare-metal stents (BMS) in SVGs
reported higher mortality in the DES group at 32 months.
Methods In the SOS trial, 80 patients with 112 lesions in 88 SVGs were randomized to a BMS or
paclitaxel-eluting stent (PES) and demonstrated improved short-term angiographic and clinical out-
comes with PES. Extended clinical follow-up was subsequently obtained.
Results Mean age was 67  9 years, and all patients were men. The indications for stenting included
acute coronary syndrome in 60% and stable angina in 31% of patients. The mean SVG age was 12  6
years. The baseline characteristics of the patients in the 2 study groups were similar. Procedural success
was achieved in 77 patients (96%). During a median follow-up of 35 months, compared with patients
randomized to BMS, those receiving PES had a lower incidence of myocardial infarction (hazard ratio
[HR]: 0.32, p  0.01), target lesion revascularization (HR: 0.20, p  0.004), target vessel revascularization
(HR: 0.41, p  0.03), and target vessel failure (HR: 0.34, p  0.001) as well as a trend toward less deﬁnite
or probable stent thrombosis (HR: 0.15, p  0.08). All-cause mortality (HR: 2.04, p  0.19) and cardiac
mortality (HR: 0.62, p  0.51) did not differ between groups.
Conclusions During long-term follow-up, use of PES was associated with signiﬁcantly better clinical out-
comes than BMS in SVG lesions. (Stenting of Saphenous Vein Grafts Trial [SOS]; NCT00247208) (J Am
Coll Cardiol Intv 2011;4:176–82) © 2011 by the American College of Cardiology Foundation
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177Whether drug-eluting stents (DES) provide superior clini-
cal outcomes compared with bare-metal stents (BMS) when
used in saphenous vein graft (SVG) lesions remains contro-
versial. Although 7 angiographic studies have all reported
consistent reduction in in-stent late loss with DES than
BMS in SVGs, the impact of DES on clinical outcomes has
varied: approximately one-half of the published comparative
studies suggested benefit with DES and one-half revealed
no difference between DES and BMS (1). Only 2
randomized-controlled trials of DES versus BMS have been
published to date. The RRISC (Reduction of Restenosis In
Saphenous Vein Grafts With Cypher Sirolimus-Eluting
Stent) trial compared a sirolimus-eluting stent (Cypher,
Cordis, Warren, New Jersey) with a BMS of similar design
(2,3). The SOS (Stenting of Saphenous Vein Grafts) trial
compared a paclitaxel-eluting stent (PES) (Taxus, Boston
Scientific, Natick, Massachusetts) to a similar BMS (4–6).
In the RRISC trial, an initial benefit seen at 6 months (2)
was no longer present at a median of 32 months of
follow-up; moreover, the DES group had higher mortality
(3). In the SOS trial, an angiographic and clinical benefit
was seen with PES during a median follow-up of 18
months. Here, we report the long-term outcomes of pa-
tients enrolled in the SOS trial.
Methods
The primary results of the SOS trial have been published
(4). The SOS trial was a randomized, controlled, single-
blinded, multicenter trial designed to test the hypothesis
that implantation of PES in SVG lesions would result in
lower 12-month angiographic restenosis rate compared with
the rates for a similar BMS (Express2, Boston Scientific).
epeat angiography was performed in 83% of patients.
atients were asked to return for repeat coronary angiogra-
hy 12 months after stent implantation and were contacted
y phone until 24 months after enrollment to determine
hether any late cardiovascular events had occurred. The
OS trial was approved by each participating site’s Institu-
ional Review Board, and all patients provided written
nformed consent. Due to concerns about the long-term
utcomes after DES implantation in SVGs, Institutional
eview Board approval was obtained to contact the patients
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In the present analysis, we examined the incidence of
everal clinical end points (death, target lesion revascular-
zation, target and nontarget vessel revascularization, target
essel failure, device-oriented composite end point, major
dverse cardiac events, and stent thrombosis) during the
ollow-up period. Myocardial infarctions (MIs) included in
he present analysis were those occurring during follow-up,
ithout including periprocedural cardiac biomarker in-
reases. Target vessel failure was defined as the composite
nd point of cardiac death, MI, and target vessel revascu-
arization. A composite end point of cardiac death, MI
ttributed to the target vessel, and target lesion revascular-
zation was also evaluated (device-oriented composite end
oint, as suggested by Cutlip et al. [7]). For this analysis, if
n adverse event could not unequivocally be attributed to a
ontarget vessel, the event was considered to represent
arget-vessel failure. We also assessed the incidence of major
dverse cardiac events defined as the composite of any
eath, any MI, or any coronary revascularization (similar to
he patient-oriented composite end point suggested by
utlip et al. [7]).
The incidence of these end
oints was calculated using the
aplan-Meier method, and the
ifferences between the 2 study
roups were compared using the
og-rank test. Cox proportional
azards methods were used to cal-
ulate the hazard ratios for the
ES versus BMS groups for each
f the end points. All analyses were performed on an intention-
o-treat principle using JMP 8 (SAS Institute, Cary, North
arolina) and SPSS (SPSS Inc., Chicago, Illinois). A 2-sided
value 0.05 was considered statistically significant.
esults
Patient characteristics. Between 2005 and 2007, 80 patients
ere enrolled in the SOS trial and were randomized to a
MS (n  39) or a PES (n  41). Mean age was 67  9
ears and all patients were men. The 2 study groups had similar
aseline clinical and procedural characteristics (Table 1). The
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Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SVG  saphenous vein graftccepted October 5, 2010.
on; PES
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178indications for angiography and stenting included acute coro-
nary syndrome in 60% and stable angina in 31%. The mean
SVG age was 12 6 years. The territory supplied by the target
SVGs was the left anterior descending artery in 28%, circum-
flex in 38%, and right coronary artery in 34%. An embolic
protection device was used in 54% of the lesions. Procedural
success was achieved in 77 patients (96%).
Long-term outcomes. The clinical outcomes during a me-
dian follow-up of 35 months are presented in Figure 1 and
Table 2.
Overall, 52 of 80 patients who participated in the SOS
trial experienced at least 1 major adverse cardiac event
during long-term follow-up: 30 of 39 BMS patients and 22
of 41 PES patients. The major adverse cardiac events were
related to the target SVG in 77% of BMS versus 45% of
PES patients and were not related to the target SVG in 7%
Table 1. Baseline Characteristics of the Study Popul
(Patients 
(Lesions  5
Age, yrs* 6
Men 3
Years since coronary artery bypass surgery* 1
Indication for PCI
Stable angina 1
Unstable angina 1
Non–ST-segment elevation acute
myocardial infarction
Other
Hypertension 3
Hyperlipidemia 3
Diabetes mellitus 1
Current smoking
Prior myocardial infarction 2
Number of lesions treated per patient* 1.4
1 2
2 1
3
4
Number of stents in each study SVG* 1.4
1 2
2 1
3
Number of stents per lesion* 1.1
1 4
2
Embolic protection device use 3
Total stent length per patient, mm* 2
Total stent length per lesion, mm* 2
Range
Post-PCI myocardial infarction 2/3
*Values are mean SD or n (%).
BMS bare-metal stent(s); PCI percutaneous coronary interventiof BMS versus 41% of PES patients; the relationship to thetarget SVG could not be determined in 17% of the BMS
versus 14% of the PES patients (p  0.01).
Five patients in the BMS and 10 in the PES group died
during follow-up (log rank, p 0.19) (Fig. 1). The cause of
death in the BMS group was cardiac arrest in 1 patient,
sudden in 2 patients, and unknown in 2 patients. In the PES
group, death was due to MI in 1 patient, end-stage heart
failure in 1 patient, unknown cause in 1 patient, and
noncardiac causes in the remaining 7 patients (lung cancer
in 4 patients, small bowel obstruction, multiple strokes and
pneumonia, and chronic obstructive pulmonary disease,
each in 1 patient).
A total of 25 patients (18 in the BMS and 7 in the PES
group) experienced a MI during follow-up. In the BMS
group, the MI was related to the target SVG in 9 of 18
patients (due to in-stent restenosis in 4 patients, stent
rafts  43)
tents  62)
PES
(Patients  41) (Grafts  45)
(Lesions  57) (Stents  62) p Value
66 9 0.71
%) 41 (100%) 1.0
11 6 0.84
0.53
) 12 (29%)
) 16 (39%)
) 10 (24%)
) 3 (7%)
) 38 (93%) 0.69
) 40 (98%) 0.53
) 18 (44%) 0.98
) 12 (29%) 0.53
) 23 (56%) 0.79
64 1.39 0.70 0.89
) 29 (71%) 0.71
) 9 (22%)
2 (5%)
1 (2%)
63 1.40 0.65 0.55
) 31 (69%) 0.81
) 10 (22%)
4 (9%)
34 1.09 0.29 0.50
) 52 (91%) 0.50
) 5 (9%)
) 29 (51%) 0.56
28 17 0.74
20 10 0.75
8–56
2/35 (6%) 0.87
 paclitaxel-eluting stent(s); SVG saphenous vein graft.ation
BMS
39) (G
5) (S
7 9
9 (100
2 6
3 (33%
4 (36%
8 (21%
4 (10%
7 (95%
7 (95%
7 (44%
9 (23%
3 (59%
1 0.
6 (67%
0 (26%
3 (8%)
0
2 0.
8 (65%
2 (28%
3 (7%)
3 0.
8 (87%
7 (13%
1 (56%
9 16
1 9
8–60
0 (7%)thrombosis in 4 patients, and progression of intermediate
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179Figure 1. Kaplan-Meier Curves of the Study’s Clinical End Points
There was no difference in all-cause mortality between the study groups (A). The incidence of myocardial infarction (B), target lesion revascularization (C), and
target vessel failure (D) (composite end point of cardiac death, myocardial infarction, and target vessel revascularization) was signiﬁcantly lower in the paclitaxel-
eluting stent (PES) group than the bare-metal stent (BMS) group.Table 2. Long-Term Clinical Outcomes in the SOS Trial
Clinical Event BMS (n  39) PES (n  41) Hazard Ratio (95% CI) p Value
Death 5 (13%) 10 (24%) 2.04 (0.70–6.0) 0.19
Cardiac death 5 (13%) 3 (7%) 0.62 (0.15–2.60) 0.51
Myocardial infarction 18 (46%) 7 (17%) 0.32 (0.13–0.76) 0.01
Target lesion revascularization 16 (41%) 4 (10%) 0.20 (0.07–0.60) 0.004
Target vessel revascularization 19 (49%) 9 (22%) 0.41 (0.19–0.90) 0.03
Any revascularization 24 (62%) 10 (24%) 0.32 (0.15–0.67) 0.003
Death or myocardial infarction 20 (51%) 16 (39%) 0.64 (0.33–1.23) 0.18
Target vessel failure 28 (72%) 14 (34%) 0.34 (0.18–0.66) 0.001
Device-oriented composite end point 25 (64%) 11 (27%) 0.28 (0.13–0.59) 0.001
Overall major adverse cardiac events
(patient-oriented composite end point)
30 (77%) 22 (54%) 0.82 (0.47–1.44) 0.49
Deﬁnite or probable stent thrombosis by ARC criteria 6 (15%) 1 (2%) 0.15 (0.02–1.26) 0.08
Values are n (%), unless otherwise specified.ARC Academic Research Consortium; CI confidence interval; SOS Stenting of Saphenous Vein Grafts; other abbreviations as in Table 1.
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180lesion in 1 patient), was not related to the target SVG in 4
patients, or its relationship to the target SVG could not be
determined in 5 patients. In the PES group, the MI was
related to the target SVG in 3 of 7 patients (due to in-stent
restenosis in 2 patients, and progression of an intermediate
lesion in 1 patient), was not related to the target SVG in 3
patients, or its relationship to the target SVG could not be
determined in 1 patient. The type of MI was non–ST-
segment elevation in 21 patients (15 in the BMS and 6 in
the PES group), ST-segment evaluation in 1 patient (in the
BMS group), or unknown in 3 patients.
The incidence of target lesion and target vessel revascu-
larization was significantly lower in the PES group (Ta-
ble 1). Stroke occurred in 1 patient (in the PES group) who
subsequently died. Use of clopidogrel was similar in the
BMS and PES groups at 1 year (73% vs. 84%), 2 years (67%
vs. 50%), and 3 years (55% vs. 58%) after enrollment.
Discussion
This extended analysis of the SOS trial suggests that
placement of a PES in SVG lesions continued to provide
benefit during a median follow-up period of 35 months
compared with BMS.
The role of DES in SVG remains controversial. Five meta-
Table 3. Long-Term Outcomes in Published Studies of DES Versus BMS in
First Author
(Ref. #) (Year)
Mean Follow-Up
(Months)
BMS
(n)
DES
(n) DES Type
Retrospective studies
Minutello (14) (2007) 20 50 59 SES
Bansal (15) (2008) 33 72 37 95% SES
Gioia (16) (2008) 24 119 106 45% SES, 46% PES
8% tacrolimus-
eluting
Ramana (17) (2008) 34 170 141 SES
Applegate (18) (2008) 24 74 74 91% SES, 9% PES
Assali (19) (2008) 24 43 68 SES, PES
van Twisk (20) (2008) 48 128 122 SES, PES
Guo (21) (2008) 12 47 50 SES, PES
Lozano (22) (2009) 30 median 114 98 NR
Shishehbor (23) (2009) 35 median 349 217 NR
Goswami (24) (2009) 36 95 284 84% SES, 16% PES
Brodie (25) (2009) 24 343 785 59% SES, 38% PES
3% both
Latib (26) (2010) 24 131 127 SES, PES
Baldwin (27) (2010) 36 192 203 63% SES, 30% PES
7% both
Prospective studies
Jeger (28) (2008) 18 13 34 65% SES, 35% PES
RRISC (2,3) (2006, 2007) 32 median 37 38 SES
SOS (4) (present) 35 median 39 41 PES
DES drug-eluting stent(s); MImyocardial infarction; NR not reported; NS not significant; SESanalyses (8–12) and 1 systematic review (1) comparing DES mwith BMS in SVG lesions have recently been published. All
showed reduction in target vessel revascularization with DES.
One meta-analysis also revealed reduction in MI with DES
(8), and 2 suggested reduction in mortality (10,11) with DES.
owever, the results of these meta-analyses and systematic
eviews were driven by the retrospective, uncontrolled studies
hat provided most of the analyzed data. As a result, the
ong-term outcomes presented in this analysis of the random-
zed SOS trial provide an important addition to the literature.
ong-term follow-up is particularly important because of the
igh risk of intermediate SVG lesion progression (13) that
ould cancel out some of the early reduction in target vessel
evascularization provided by DES.
Whether DES implantation in SVGs provides long-term
enefit has also been controversial. The results of 17 published
tudies reporting 12-month clinical outcomes after DES
ersus BMS implantation in SVGs are summarized in Table 3
2–4,14–28). Only 5 of 14 retrospective studies (14,19,21,26,28)
eported a reduction in target vessel revascularization with
ES implantation. However, similar to the meta-analyses, a
ajor limitation is the retrospective nature of most long-term
utcome studies. The prospective and randomized RRISC
rial provides the best quality long-term comparative analysis to
ate (3,29), in which mortality at a median follow-up of 32
esions
Death (%) MI (%) TVR (%)
S DES p Value BMS DES p Value BMS DES p Value
6.8 0.51 2.0 6.8 0.37 36 15.3 0.01
19 0.68 NR NR NR 42 35 0.47
6 0.9 1 2 0.8 14 14 0.9
6 0.05 9 5 0.19 16 13 0.52
6 0.79 15 11 0.40 17 10 0.18
.7 2.9 0.6 7 8.8 0.9 27.9 10.3 0.02
22.5 NS 11.1 7.6 NS 31 18.4 NS
2.0 0.32 4.2 0 0.30 25.5 10 0.05
R NR NR NR NR NR 13 17 0.49
13 NS 6 7 NS 6 13 NS
.6 18.6 NS 3.4 9.6 NS 10.6 10.6 NS
.7 8.2 0.005 11.3 11.9 0.06 16.9 18.3 0.86
.8 8.7 0.99 9.4 6.3 0.50 24.2 19.7 0.47
.1 16.8 0.73 18.6 16.1 0.39 22.2 23.0 0.88
R NR NR 0 6 1.0 46 18 0.045
29 0.001 5 18 0.15 38 34 0.74
24 0.19 46 17 0.01 49 22 0.03
us-eluting stent(s); TVR target vessel revascularization; other abbreviations as in Tables 1 and 2.SVG L
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181vs. 0%, p  0.001) and there was no reduction with DES in
the incidence of target vessel revascularization. Several expla-
nations for the different results observed in the SOS and
RRISC trials could be proposed. First, different DES were
used: a sirolimus-eluting stent was used in RRISC versus a
PES in SOS. Sirolimus-eluting stent did not show benefit in a
large prospective cohort study (30), whereas PES have shown
excellent results in SVGs in the ARRIVE (TAXUS Peri-
Approved Registry: A Multicenter Safety Surveillance) 1 and 2
registries (31) and in the VELETI (Treatment of Moderate
Vein Graft Lesions With Paclitaxel Drug Eluting Stents) trial,
in which stenting of intermediate (30% to 60%) SVG lesions,
compared with medically treated lesions, was associated with
significant reduction in disease progression (13). A recent
comparison between patients who underwent SVG stenting
with either a sirolimus-eluting stent or PES in the Southern
California Registry, showed a trend for higher target vessel
revascularization with sirolimus-eluting stents (hazard ratio:
2.54, p 0.09) (32), although 2 small and underpowered prior
tudies (33,34) did not show any difference between the 2
tents. Whether various DES have different efficacy and safety
n SVGs, and whether such differences are due to the drug
luted or the elution rate, remains to be determined (35).
econd, patients in the DES arm of RRISC had excessive
ortality compared with what would be expected based on
revious SVG stenting studies (36,37) (11% per year in
RISC compared with 5% to 7% in other studies, including
OS); moreover, the BMS arm of RRISC surprisingly had no
eaths during 2.7 years. However, most deaths in the DES
rm of RRISC were not related to the study SVG: 3 of 11
eaths were noncardiac, 3 of 11 were cardiac but proven to not
e related to the study SVG, 3 were sudden deaths and only 2
ere confirmed to be related to the study SVG (1 in-stent
estenosis requiring redo coronary arterial bypass graft surgery
n 1 patient and 1 perioperative stent thrombosis 14.5 months
fter implantation after antiplatelet therapy was discontinued
efore knee surgery) (3). Similarly, in the SOS trial, 7 of 10
deaths in the PES arm were noncardiac, highlighting the high
overall risk and multiple comorbidities of patients who need
SVG stenting. Third, there were significant differences be-
tween the 2 study populations: patients enrolled in RRISC
were older (mean age 73 years vs. 67 years in SOS), less likely
to have diabetes mellitus (15% vs. 44% in SOS), and received
shorter duration of mandatory antiplatelet therapy (12 months
in SOS vs. 2 months in RRISC). Moreover, in the SOS trial,
more major adverse cardiac events were related to the target
SVG in the BMS than the PES group (77% vs. 45%),
suggesting that the benefit observed with PES was likely
related to improved outcomes in the target SVG.
Although DES are used in most SVG interventions in the
U.S. (38), there remains an unmet need for large, prospective,
randomized-controlled trials to better delineate both the short-
and long-term outcomes after DES implantation. Three such
trials are ongoing: 1) the ISAR-CABG (Prospective, Ran-domized Trial of Drug-Eluting Stents versus Bare Metal
Stents for the Reduction of Restenosis in Bypass Grafts) trial;
2) the BASKETSAVAGE (Basel Stent Kosten Effektivitäts
Trial—Saphenous Venous Graft Angioplasty Using Glyco-
protein IIb/IIIa Receptor Inhibitors and Drug-Eluting Stents)
trial; and 3) the DIVA (VA Cooperative Study #571, Drug
Eluting Stents in Saphenous Vein Graft Angioplasty) trial (1).
hese studies, once completed, will provide a significantly
mproved understanding of the role of DES in SVGs.
Study limitations. First, this was a non-pre-specified, post
oc analysis of the SOS trial, and the results should be
iewed as hypothesis-generating. Second, all study patients
ere men, and even though sex differences are unlikely to
ontribute to the findings of this study, extrapolation of the
esults to women should be done with caution. Third, due
o the relatively small sample size, it is subject to both type
and type II statistical error, although the study findings
ere consistent between the early and long-term follow-up
eriods.
onclusions
In the prospective, randomized SOS trial, implantation of
PES, when compared with BMS, was associated with im-
proved long-term clinical outcomes, suggesting that PES may
provide significant benefit in this high-risk patient population.
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